BIO-TECHNE Corp (TECH) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 156.57M; Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 156.57M | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 156.57M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-03-31 | 156.57M | (m) | (m) |
| 2025-12-31 | 156.45M | (m) | (m) |
| 2025-09-30 | 155.81M | (m) | (m) |
| 2025-03-31 | 156.77M | (m) | (m) |
| 2024-12-31 | 158.09M | (m) | (m) |
| 2024-09-30 | 158.89M | (m) | (m) |
| 2024-03-31 | 157.58M | (m) | (m) |
| 2023-12-31 | 157.19M | (m) | (m) |
| 2023-09-30 | 158.15M | (m) | (m) |
| 2023-03-31 | 157.44M | (m) | (m) |
| 2022-12-31 | 157.28M | (m) | (m) |
| 2022-09-30 | 39.24M | (m) | (m) |
| 2022-03-31 | 39.23M | (m) | (m) |
| 2021-12-31 | 39.29M | (m) | (m) |
| 2021-09-30 | 39.30M | (m) | (m) |
| 2021-03-31 | 38.89M | (m) | (m) |
| 2020-12-31 | 38.80M | (m) | (m) |
| 2020-09-30 | 38.61M | (m) | (m) |
| 2020-03-31 | 38.22M | (m) | (m) |
| 2019-12-31 | 38.35M | (m) | (m) |
| 2019-09-30 | 38.11M | (m) | (m) |
| 2019-06-30 | 38.06M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |